CDK4 and breast cancer: Moreover, Jin and colleagues proved that the lncRNA TROJAN resulted in the upregulation of CDK2 by binding NKRF (and impeding its inhibitory effect on RELA/p65), hence favoring a reduced sensitivity of ER+ BC cells to CDK4/6i [53].